Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells ...

For years, researchers have been trying to figure out how to treat inherited blood disorders like sickle cell disease without causing new health problems in the process. Now, a team of scientists from ...

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr ...

A research group led by Associate Professor Tetsuya Muramoto from the Faculty of Science, Toho University, has established a ...

Genomics (NasdaqGS:TXG) is collaborating with PerturbAI, NVIDIA, and the Allen Institute on what is described as the largest in vivo CRISPR brain atlas. The partnership combines 10x Genomics' single ...

Revvity's Dharmacon All-in-one lentiviral platform has expanded to include whole-genome library options for CRISPR knockout (CRISPRko), CRISPR interference (CRISPRi), and CRISPR activation (CRISPRa).

Tools like CRISPR-Cas9 are creating new opportunities for innovation in St. Louis, as well as risks around IP protection and regulation.

Co‑injecting three common amino acids with LNPs dramatically boosted both mRNA delivery and CRISPR gene editing efficiency in preclinical models.

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $46.93, demonstrating a -1.59% change from the preceding day's closing price. This change lagged the S&P 500's 0.28% loss on the day.